Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Significant Increase in Short Interest

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a large growth in short interest in May. As of May 31st, there was short interest totalling 366,900 shares, a growth of 93.5% from the May 15th total of 189,600 shares. Currently, 1.0% of the company’s stock are short sold. Based on an average trading volume of 2,550,000 shares, the days-to-cover ratio is presently 0.1 days.

Biodexa Pharmaceuticals Stock Performance

NASDAQ BDRX opened at $1.07 on Friday. Biodexa Pharmaceuticals has a one year low of $1.01 and a one year high of $41.50. The firm’s fifty day moving average is $1.33 and its two-hundred day moving average is $2.87.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.